Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01151124Phase 1Completed

Pilot Investigation of Stem Cells in Stroke

Role: lead

NCT02464436Phase 1Unknown

Safety and Tolerability of hRPC in Retinitis Pigmentosa

Role: lead

NCT05598775Enrolling By Invitation

Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study

Role: lead

NCT03629275Phase 2Terminated

Investigation of Neural Stem Cells in Ischemic Stroke

Role: lead

NCT02117635Phase 2Completed

Pilot Investigation of Stem Cells in Stroke Phase II Efficacy

Role: lead

NCT01916369Phase 1Completed

Safety Trial Of CTX Cells In Patients With Lower Limb Ischaemia

Role: lead

NCT03333980Completed

An Ischaemic Stroke Observational Study

Role: lead

NCT01859572Completed

Observational Study of Ischaemic Stroke

Role: lead

All 8 trials loaded